$TCRT News

Alaunos Therapeutics Reports Preclinical Results For ALN1003 Showing Weight Loss, Improved Insulin Sensitivity, And Better Liver Health In Obese Mouse Studies

Alaunos Therapeutics Issues Updated Preclinical Data From Non-GLP Diet-Induced Obesity Mouse Studies Evaluating ALN1003, Investigational Oral Metabolic Therapeutic Candidate

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

Alaunos Therapeutics Announces Early Data From Two Non-GLP DIO Mouse Studies Evaluating ALN1003 For Treating Obesity And Related Conditions

Ziopharm: Q3 Earnings Snapshot

4 Biotech Stocks That Are Showing Weakness: Momentum Scores Fading Over The Past Week

Ziopharm: Q2 Earnings Snapshot

Alaunos Therapeutics Q2 EPS $(0.63) Up From $(0.71) YoY

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

Alaunos Therapeutics Enters Equity Purchase Agreement With Mast Hill; Mast Hill To Purchase Up To $25M Of Common Stock

PMGC Capital LLC, a Subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB), To File Schedule 13D Reporting 5.09% Stake in Alaunos Therapeutics, Inc. (Nasdaq: TCRT)

Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy

TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q2 2024

Ziopharm: Q2 Earnings Snapshot

Alaunos Therapeutics shares are trading lower after the company announced a 1-for-10 reverse stock split.

Tuesday, Alaunos Therapeutics Announced A Reversed Stock Split Of 1-for-10, Effective July 18-8K

ZIOPHARM Oncology trading halted, news pending

12 Health Care Stocks Moving In Friday's Pre-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session